Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial

BACKGROUND: The JACOB trial (NCT01774786) was a double-blinded, placebo-controlled, randomized, multicenter, international, phase III trial evaluating the efficacy and safety of adding pertuzumab to trastuzumab and chemotherapy in first-line treatment of human epidermal growth factor receptor 2 (HER...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tianshu, Qin, Yanru, Li, Jin, Xu, Ruihua, Xu, Jianming, Yang, Shujun, Qin, Shukui, Bai, Yuxian, Wu, Changping, Mao, Yixiang, Wu, Haiyan, Ge, Yilin, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591878/
https://www.ncbi.nlm.nih.gov/pubmed/31234927
http://dx.doi.org/10.1186/s40880-019-0384-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591878/
https://www.ncbi.nlm.nih.gov/pubmed/31234927
http://dx.doi.org/10.1186/s40880-019-0384-6

Ejemplares similares